We analyzed cost effectiveness of buprenorphine/naloxone combination and sustained release (SR) morphine when compared to methadone in patients treated for opioid dependence in Slovenia. To compare the expected costs of treatment with buprenorphine/naloxone combination and SR morphine, we also performed cost-minimization analysis. (Source: Value in Health)

We analyzed cost effectiveness of buprenorphine/naloxone combination and sustained release (SR) morphine when compared to methadone in patients treated for opioid dependence in Slovenia. To compare the expected costs of treatment with buprenorphine/naloxone combination and SR morphine, we also performed cost-minimization analysis. (Source: Value in Health)

Standard-of-care for opioid addiction is substitution therapy with methadone, buprenorphine, or buprenorphine/naloxone. As EU5 healthcare budgets tighten, this study explored how emerging brands may gain a foothold in this increasingly generic market, as payers and prescribers balance clinical need with limited funds. (Source: Value in Health)

Standard-of-care for opioid addiction is substitution therapy with methadone, buprenorphine, or buprenorphine/naloxone. As EU5 healthcare budgets tighten, this study explored how emerging brands may gain a foothold in this increasingly generic market, as payers and prescribers balance clinical need with limited funds. (Source: Value in Health)

Authors: Badri PS, Dutta S, Wang H, Podsadecki TJ, Polepally AR, Khatri A, Zha J, Chiu YL, Awni WM, Menon RM
Abstract
The 2D regimen of ombitasvir and paritaprevir (administered with low-dose ritonavir) is being developed for treatment of genotype subtype 1b and genotypes 2 and 4 chronic hepatitis C virus (HCV) infection. Drug-drug interactions were evaluated in healthy volunteers to develop dosing recommendations for HCV-infected subjects. Mechanism-based interactions were evaluated for ketoconazole, pravastatin, rosuvastatin, digoxin, warfarin, and omeprazole. Interactions were also evaluated for duloxetine, escitalopram, methadone, and buprenorphine/naloxone. Ratios of geometric means with 90% confidence intervals for maximum plasma concentration and area under the plasma concen…

Authors: Badri PS, Dutta S, Wang H, Podsadecki TJ, Polepally AR, Khatri A, Zha J, Chiu YL, Awni WM, Menon RM
Abstract
The 2D regimen of ombitasvir and paritaprevir (administered with low-dose ritonavir) is being developed for treatment of genotype subtype 1b and genotypes 2 and 4 chronic hepatitis C virus (HCV) infection. Drug-drug interactions were evaluated in healthy volunteers to develop dosing recommendations for HCV-infected subjects. Mechanism-based interactions were evaluated for ketoconazole, pravastatin, rosuvastatin, digoxin, warfarin, and omeprazole. Interactions were also evaluated for duloxetine, escitalopram, methadone, and buprenorphine/naloxone. Ratios of geometric means with 90% confidence intervals for maximum plasma concentration and area under the plasma concen…

ConclusionsTwo years post‐introduction, levels of BNX film diversion and injection remained comparable with those for methadone and BNX tablets, and lower than mono‐buprenorphine. We found no evidence that BNX film has lower non‐adherence and diversion than the tablet formulation. [Larance B, Mattick R, Ali R, Lintzeris N, Jenkinson R, White N, Kihas I, Cassidy R, Degenhardt L. Diversion and injection of buprenorphine–naloxone film two years post‐introduction in Australia. Drug Alcohol Rev 2015] (Source: Drug and Alcohol Review)

ConclusionsTwo years post‐introduction, levels of BNX film diversion and injection remained comparable with those for methadone and BNX tablets, and lower than mono‐buprenorphine. We found no evidence that BNX film has lower non‐adherence and diversion than the tablet formulation. [Larance B, Mattick R, Ali R, Lintzeris N, Jenkinson R, White N, Kihas I, Cassidy R, Degenhardt L. Diversion and injection of buprenorphine–naloxone film two years post‐introduction in Australia. Drug Alcohol Rev 2015] (Source: Drug and Alcohol Review)

The objective was to estimate the annual interaction management cost of agonist opioid treatment (AOT) for opioid-dependent (OD) patients with buprenorphine-naloxone (Suboxone®) (B/N) or methadone associated with concomitant treatments for infectious (HIV) or psychiatric comorbidities. A costs analysis model was developed to calculate the associated cost of AOT and interaction management. The AOT cost included pharmaceutical costs, drug preparation, distribution and dispensing, based on intake regimen (healthcare center or take-home) and type and frequency of dispensing (healthcare center or pharmacy), and medical visits. The cost of methadone also included single-dose bottles, monthly costs of custody at pharmacy, urine toxicology drug screenings and nursing visits. Potential interaction…

The objective was to estimate the annual interaction management cost of agonist opioid treatment (AOT) for opioid-dependent (OD) patients with buprenorphine-naloxone (Suboxone®) (B/N) or methadone associated with concomitant treatments for infectious (HIV) or psychiatric comorbidities. A costs analysis model was developed to calculate the associated cost of AOT and interaction management. The AOT cost included pharmaceutical costs, drug preparation, distribution and dispensing, based on intake regimen (healthcare center or take-home) and type and frequency of dispensing (healthcare center or pharmacy), and medical visits. The cost of methadone also included single-dose bottles, monthly costs of custody at pharmacy, urine toxicology drug screenings and nursing visits. Potential interaction…